Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells

[1]  Ryuji Kobayashi,et al.  Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. , 2005, Cancer research.

[2]  D. Hicklin,et al.  A Fully Human Recombinant IgG-like Bispecific Antibody to Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor for Enhanced Antitumor Activity* , 2005, Journal of Biological Chemistry.

[3]  R. Vessella,et al.  In vivo Effects of the Human Type I Insulin-Like Growth Factor Receptor Antibody A12 on Androgen-Dependent and Androgen-Independent Xenograft Human Prostate Tumors , 2005, Clinical Cancer Research.

[4]  Stephen L. Abrams,et al.  Effects of Endogenous Epidermal Growth Factor Receptor Signaling on DNA Synthesis and ERK Activation in a Cytokine-Dependent Hematopoietic Cell Line , 2005, Cell cycle.

[5]  Stephen L. Abrams,et al.  Conditional EGFR Promotes Cell Cycle Progression and Prevention of Apoptosis in the Absence of Autocrine Cytokines , 2005, Cell cycle.

[6]  L. Schwartz,et al.  Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Mark W Tengowski,et al.  Combination Therapy Enhances the Inhibition of Tumor Growth with the Fully Human Anti–Type 1 Insulin-Like Growth Factor Receptor Monoclonal Antibody CP-751,871 , 2005, Clinical Cancer Research.

[8]  R. Bataille,et al.  CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. , 2005, Haematologica.

[9]  C. Singer,et al.  Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer , 2005, Journal of Cancer Research and Clinical Oncology.

[10]  J. McCubrey,et al.  Effects of a conditionally active v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and abrogation of cytokine dependency of hematopoietic cells , 2004, Oncogene.

[11]  T. Libermann,et al.  Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. , 2004, Cancer cell.

[12]  P. Bohlen,et al.  Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor Signaling Pathways in Cancer Cells with a Fully Human Recombinant Bispecific Antibody* , 2004, Journal of Biological Chemistry.

[13]  F. Peruzzi,et al.  The IGF‐1 receptor in cancer biology , 2003, International journal of cancer.

[14]  Peter Bohlen,et al.  A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. , 2003, Cancer research.

[15]  D. Roith.  The Insulin-Like Growth Factor System , 2003, Experimental Diabesity Research.

[16]  C. Roberts,et al.  The insulin-like growth factor system and cancer. , 2003, Cancer letters.

[17]  M. Rolfe,et al.  Anticancer antibodies. , 2003, American journal of clinical pathology.

[18]  R. Baserga,et al.  IGF-I receptor signalling in transformation and differentiation , 2001, Molecular pathology : MP.

[19]  M. Glennie,et al.  Clinical trials of antibody therapy. , 2000, Immunology today.

[20]  J. Blatt.  IGF1 AND LEUKEMIA , 2000, Pediatric hematology and oncology.

[21]  I. Shimon,et al.  The insulin-like growth factor system in regulation of normal and malignant hematopoiesis. , 1995, Leukemia research.

[22]  G. Freund,et al.  Functional insulin and insulin-like growth factor-1 receptors are preferentially expressed in multiple myeloma cell lines as compared to B-lymphoblastoid cell lines. , 1994, Cancer research.

[23]  J. McCubrey,et al.  Growth-promoting effects of insulin-like growth factor-1 (IGF-1) on hematopoietic cells: overexpression of introduced IGF-1 receptor abrogates interleukin-3 dependency of murine factor-dependent cells by a ligand-dependent mechanism. , 1991, Blood.